MET and melanoma: Another potential explanation is that activation of alternative signaling pathways may, in part, explain these results; indeed, the melanoma cell line that lacked an apparent response to MET inhibition, SK-MEL-28, has, for example, an EGFR mutation (see Supplemental Table S1) that may have contributed to this phenomenon.